Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Apyx Medical (APYX) Long-Term Debt Issuances (2023)

Apyx Medical posted quarterly Long-Term Debt Issuances of $34.2 million for Q4 2023, up 268.02% on a QoQ basis from $9.3 million in Q1 2023.

Apyx Medical (APYX) has 1 years of Long-Term Debt Issuances data on file, last reported at $34.2 million in Q4 2023.

  • For the quarter ending Q4 2023, Long-Term Debt Issuances changed N/A year-over-year to $34.2 million; the trailing twelve-month figure through Sep 2024 stood at $34.2 million (up 268.02% YoY), and the FY2023 full-year result was $43.5 million, changed N/A from the prior year.
  • Long-Term Debt Issuances for Q4 2023 stood at $34.2 million, up from $9.3 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $34.2 million in Q4 2023 and bottomed at $9.3 million in Q1 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 19.86 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 11.71 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 1.15 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Apyx Medical 174.53 Mn 143.65 Mn 7.93 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 34.19 Mn
Dec 31, 2023 34.19 Mn
Mar 31, 2023 9.29 Mn
Mar 31, 2023 9.29 Mn